Portrait of a man with Beauty by Buford branding.
Accessibility Accessibility icon
CONSULTATION (303) 951-5829
Accent Image
Kybella Summer Special

Kybella Summer Special

August 3, 2015

Slide25To help introduce our Colorado patients to Kybella–the latest treatment for reducing your double-chin–we are offering a special incentive to our valued clients throughout the month of August.  For this month only, all patients will receive the following promotional incentive:

  • Special pricing of $1200/treatment

To achieve maximal results, most patients require 2-3 treatments spaced 6-8 weeks apart.  Downtime is minimal but there is swelling immediately after the procedure which can last (in some cases) for up to a week or more.

To learn more about this exciting new procedure, please CLICK HERE.  To best determine if Kybella is right for you, we are asking potential candidates to forward a series of three facial photos (frontal view/left side view/right side view) to us at melanie@beautybybuford.com.  Your photos will be reviewed and one of our team members will contact you with more information.

We are also looking for potential models for upcoming training sessions.  All models will be personally injected by Nationally Certified Kybella Trainer, Gregory A. Buford, MD, FACS, PCEO.  These spaces will fill quickly so please forward your photos to melanie@beautybybuford.com and let us know if you would be interested in participating.

Thanks again for your continued support!  We look forward to working with you.

Posted by BEAUTY by BUFORD

You Might Also Like

BEAUTY by BUFORD Image

3 Reasons Why BOTOX Will Not Work For You

Sep 28, 2023
BEAUTY by BUFORD Image

Tighten and brighten your eyelid skin with no surgery and no downtime…for free!

Dec 21, 2015
BEAUTY by BUFORD Image

Tremendous savings on Belotero!

Jul 13, 2015

10459 Park Meadows Drive, Suite 100
Lone Tree, CO 80124

(303) 951-5829

Mon-Fri: 9 AM - 5 PM

4.9
from 394+ Reviews

© 2025 BEAUTY by BUFORD | All Rights Reserved

Plastic Surgery Marketing

Sitemap   |   Privacy Policy   |   Accessibility   |   Notice of Open Payment Database

Accessibility: If you are visually impaired or have some other impairment and you wish to discuss potential accommodations related to using this website, please contact our office at (303) 951-5829.

Visualize your NEW LOOK in 3D NOW

START NOW
Natrelle® Breast Implants
IMPORTANT SAFETY INFORMATION

Breast implants are not lifetime devices. The longer patients have them, the greater the chance they will develop complications, which may require more surgery. Breast implants have been associated with a cancer of the immune system called breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). Some patients have died from BIA-ALCL. Patients have also reported a variety of systemic symptoms such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases, and others.

Natrelle® Breast Implants are for breast augmentation and revision surgery in women at least 22 years old for silicone-filled implants and women at least 18 years old for saline-filled implants.

You should not get breast implants if you currently have an active infection, untreated breast cancer or precancer, or are pregnant or nursing. Tell your doctor about any conditions you have, any medications you are taking, and any planned cancer treatments. Breast implantation is likely not a one-time surgery.

Having implants removed and not replaced may lead to permanent cosmetic changes of the breasts. Breast implants may affect breastfeeding. Gel implants may rupture without symptoms, so periodic imaging after surgery is recommended.

Key complications are reoperation, implant removal, implant rupture, implant deflation with saline-filled implants, and severe capsular contracture.

Talk to your doctor for more information.

The use of Natrelle® Breast Implants is restricted to licensed physicians who provide information to patients about the risks and benefits of breast implant surgery.

Visualize your
NEW LOOK in 3D NOW!

Start now
START NOW
Natrelle® Breast Implants
IMPORTANT SAFETY INFORMATION

Breast implants are not lifetime devices. The longer patients have them, the greater the chance they will develop complications, which may require more surgery. Breast implants have been associated with a cancer of the immune system called breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). Some patients have died from BIA-ALCL. Patients have also reported a variety of systemic symptoms such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases, and others.

Breast implants are not lifetime devices. The longer patients have them, the greater the chance they will develop complications, which may require more surgery. Breast implants have been associated with a cancer of the immune system called breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). Some patients have died from BIA-ALCL. Patients have also reported a variety of systemic symptoms such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases, and others.

Breast implants are not lifetime devices. The longer patients have them, the greater the chance they will develop complications, which may require more surgery. Breast implants have been associated with a cancer of the immune system called breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). Some patients have died from BIA-ALCL. Patients have also reported a variety of systemic symptoms such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases, and others.

Breast implants are not lifetime devices. The longer patients have them, the greater the chance they will develop complications, which may require more surgery. Breast implants have been associated with a cancer of the immune system called breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). Some patients have died from BIA-ALCL. Patients have also reported a variety of systemic symptoms such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases, and others.